1 |
(pyr1)apelin-13 |
- |
- |
- |
- |
086 1件: 86 💬 |
2 |
1-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride |
Piperazine |
6件: D00807 D00807, D01393 D01393, D02127 D02127, D02145 D02145, D05486 D05486, D06224 D06224 💬 |
- |
- |
058 1件: 58 💬 |
3 |
10 milligram (mg) fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
1件: D04127 D04127 💬 |
KCNA4 4件: KCNA4, KCNC3, KCND2, KCND3 💬 |
Cortisol synthesis and secretion 4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia |
013 1件: 13 💬 |
4 |
100 mg ap1189 |
- |
- |
- |
- |
222 1件: 222 💬 |
5 |
15 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
1件: D04127 D04127 💬 |
KCNA4 4件: KCNA4, KCNC3, KCND2, KCND3 💬 |
Cortisol synthesis and secretion 4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia |
013 1件: 13 💬 |
6 |
1500mg mesalazine pellets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
7 |
20 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
1件: D04127 D04127 💬 |
KCNA4 4件: KCNA4, KCNC3, KCND2, KCND3 💬 |
Cortisol synthesis and secretion 4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia |
013 1件: 13 💬 |
8 |
20 mg sildenafil citrate by mouth |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
9 |
250mg mesalazine pellets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
10 |
4-ap |
Dalfampridine |
1件: D04127 D04127 💬 |
KCNA4 4件: KCNA4, KCNC3, KCND2, KCND3 💬 |
Cortisol synthesis and secretion 4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia |
013 1件: 13 💬 |
11 |
5% sildenafil cream |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
050 1件: 50 💬 |
12 |
50 mg ap1189 |
- |
- |
- |
- |
046 1件: 46 💬 |
13 |
500mg mesalazine pellets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
14 |
6abeta - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
15 |
6aß - apomorphine-10,11-diol hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
16 |
750mg mesalazine pellets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
17 |
90 mg hydrocortisone acetate suppository with sephure suppository applicator |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
18 |
[allo-apz2-eb] |
- |
- |
- |
- |
036 1件: 36 💬 |
19 |
Access program - sildenafil citrate, viagra, revatio |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
20 |
Adsvf application in the right hand |
- |
- |
- |
- |
051 1件: 51 💬 |
21 |
Allo-apz2-eb |
- |
- |
- |
- |
036 1件: 36 💬 |
22 |
Any other approved antiepileptic drug |
- |
- |
- |
- |
144 1件: 144 💬 |
23 |
Aodg (apigenin-7-o-glucuronide) |
Apigenin |
- |
- |
- |
097 1件: 97 💬 |
24 |
Ap |
- |
- |
- |
- |
002 4件: 2 , 6 , 13, 299 💬 |
25 |
Ap-101 |
- |
- |
- |
- |
002 1件: 2 💬 |
26 |
Ap-cd/ld |
- |
- |
- |
- |
006 1件: 6 💬 |
27 |
Ap-pa02 |
- |
- |
- |
- |
299 1件: 299 💬 |
28 |
Ap09004 |
- |
- |
- |
- |
006 1件: 6 💬 |
29 |
Ap1189 |
- |
- |
- |
- |
046 2件: 46, 222 💬 |
30 |
Ap1903 |
- |
- |
- |
- |
060 3件: 60, 285, 326 💬 |
31 |
Ap1903 a594 |
- |
- |
- |
- |
060 3件: 60, 285, 326 💬 |
32 |
Apabetalone |
Apabetalone |
1件: D11131 D11131 💬 |
- |
- |
086 1件: 86 💬 |
33 |
Apadamtase alfa |
Apadamtase alfa |
- |
- |
- |
064 1件: 64 💬 |
34 |
Apademtase alfa |
- |
- |
- |
- |
064 1件: 64 💬 |
35 |
Apcc, apcc + txa |
- |
- |
- |
- |
288 1件: 288 💬 |
36 |
Apd334 |
- |
- |
- |
- |
093 4件: 93, 96, 97, 269 💬 |
37 |
Apd371 |
- |
- |
- |
- |
096 1件: 96 💬 |
38 |
Apd421 |
- |
- |
- |
- |
107 1件: 107 💬 |
39 |
Apd811 |
- |
- |
- |
- |
086 1件: 86 💬 |
40 |
Apelin |
- |
- |
- |
- |
086 1件: 86 💬 |
41 |
Api |
- |
- |
- |
- |
231 2件: 231, 299 💬 |
42 |
Api-aat |
- |
- |
- |
- |
231 1件: 231 💬 |
43 |
Api-aat, ad00370, arc-aat, api drug substance |
- |
- |
- |
- |
231 1件: 231 💬 |
44 |
Apigenin |
Apigenin |
- |
- |
- |
097 1件: 97 💬 |
45 |
Apitox - pure honeybee toxin |
- |
- |
- |
- |
013 1件: 13 💬 |
46 |
Apixaban |
Apixaban |
1件: D03213 D03213 💬 |
F10 1件: F10 💬 |
Complement and coagulation cascades 1件: Complement and coagulation cascades |
096 3件: 96, 97, 222 💬 |
47 |
Apixaban 2.5 milligram |
Apixaban |
1件: D03213 D03213 💬 |
F10 1件: F10 💬 |
Complement and coagulation cascades 1件: Complement and coagulation cascades |
096 2件: 96, 97 💬 |
48 |
Apixaban 5 mg |
Apixaban |
1件: D03213 D03213 💬 |
F10 1件: F10 💬 |
Complement and coagulation cascades 1件: Complement and coagulation cascades |
222 1件: 222 💬 |
49 |
Apl-130277 |
- |
- |
- |
- |
006 1件: 6 💬 |
50 |
Apl-2 |
- |
- |
- |
- |
061 5件: 61, 62, 66, 222, 223 💬 |
51 |
Apla12 |
- |
- |
- |
- |
046 1件: 46 💬 |
52 |
Aplindore |
Aplindore |
- |
- |
- |
006 1件: 6 💬 |
53 |
Aplindore mr tablets |
Aplindore |
- |
- |
- |
006 1件: 6 💬 |
54 |
Apn01 |
Recombinant Human Angiotensin-Converting Enzyme 2 |
- |
- |
- |
086 1件: 86 💬 |
55 |
Apo-go |
- |
- |
- |
- |
006 1件: 6 💬 |
56 |
Apo-go® |
- |
- |
- |
- |
006 1件: 6 💬 |
57 |
Apo-p001 |
- |
- |
- |
- |
002 1件: 2 💬 |
58 |
Apokinon |
- |
- |
- |
- |
006 1件: 6 💬 |
59 |
Apokyn |
- |
- |
- |
- |
006 1件: 6 💬 |
60 |
Apomor |
- |
- |
- |
- |
006 1件: 6 💬 |
61 |
Apomorp |
- |
- |
- |
- |
006 1件: 6 💬 |
62 |
Apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
63 |
Apomorphine 0.25% (2.5mg/ml) |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
64 |
Apomorphine hcl injection |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
65 |
Apomorphine hydrochloride |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
66 |
Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
67 |
Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
68 |
Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
69 |
Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
70 |
Apomorphine hydrochloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
71 |
Apomorphine hydrocloride |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
72 |
Apomorphine hydrocloride hemihydrate |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
73 |
Apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
74 |
Apomorphine nasal powder |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
75 |
Aporon |
- |
- |
- |
- |
006 1件: 6 💬 |
76 |
Apple |
Apple |
- |
- |
- |
070 1件: 70 💬 |
77 |
Application of adalimumab |
Adalimumab |
1件: D02597 D02597 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
096 1件: 96 💬 |
78 |
Apply veregen ® 10 % on a randomized area and the moisturizing cream of the other side |
- |
- |
- |
- |
160 1件: 160 💬 |
79 |
Apratastat |
Apratastat |
1件: D08859 D08859 💬 |
ADAM17 2件: ADAM17, MMP13 💬 |
Alzheimer disease 7件: Alzheimer disease, Coronavirus disease - COVID-19, Epithelial cell signaling in Helicobacter pylori infection, IL-17 signaling pathway, Notch signaling pathway, Parathyroid hormone synthesis, secretion and action, Relaxin signaling pathway |
046 1件: 46 💬 |
80 |
Apremilast |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
046 6件: 46, 50, 56, 97, 162, 271 💬 |
81 |
Apremilast (cc-10004) |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
056 1件: 56 💬 |
82 |
Apremilast 20 mg |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
046 1件: 46 💬 |
83 |
Apremilast 30 mg |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
046 1件: 46 💬 |
84 |
Apremilast 30mg |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
050 1件: 50 💬 |
85 |
Apremilast tablet 20 mg |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
271 1件: 271 💬 |
86 |
Apremilast tablet 30 mg bid |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
271 1件: 271 💬 |
87 |
Aprinox |
- |
- |
- |
- |
067 1件: 67 💬 |
88 |
Apriso 0.375g er cap |
- |
- |
- |
- |
097 1件: 97 💬 |
89 |
Apriso 375 mg extended-release capsules |
- |
- |
- |
- |
097 1件: 97 💬 |
90 |
Aproart |
- |
- |
- |
- |
065 1件: 65 💬 |
91 |
Aprotinin |
Aprotinin |
1件: D02971 D02971 💬 |
- |
- |
028 1件: 28 💬 |
92 |
Aprovel |
- |
- |
- |
- |
167 1件: 167 💬 |
93 |
Aprovel (150 mg) |
- |
- |
- |
- |
222 1件: 222 💬 |
94 |
Aprovel 150 mg tablets |
- |
- |
- |
- |
222 1件: 222 💬 |
95 |
Apt-1011 |
- |
- |
- |
- |
098 1件: 98 💬 |
96 |
Apt-1011 - 3 mg |
- |
- |
- |
- |
098 1件: 98 💬 |
97 |
Apvo210 |
- |
- |
- |
- |
097 1件: 97 💬 |
98 |
Autologous apoptotic cells injection |
- |
- |
- |
- |
046 1件: 46 💬 |
99 |
Azathioprine or mesalazine |
Azathioprine |
3件: D00238 D00238, D00377 D00377, D03033 D03033 💬 |
- |
- |
096 1件: 96 💬 |
100 |
Bosentan and sildenafil |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
101 |
Bpr277 ointment (controlled application) |
- |
- |
- |
- |
160 1件: 160 💬 |
102 |
Brimonidine tartrate posterior segment drug delivery system (brimo ps dds) applicator system |
Brimonidine |
2件: D02076 D02076, D07540 D07540 💬 |
ADRA2A 3件: ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
090 1件: 90 💬 |
103 |
Bupropion |
Bupropion |
3件: D00817 D00817, D07591 D07591, D07938 D07938 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
008 5件: 8 , 18, 21, 96, 171 💬 |
104 |
Bupropion & citalopram |
Bupropion |
5件: D00817 D00817, D00822 D00822, D07591 D07591, D07704 D07704, D07938 D07938 💬 |
SLC6A2 3件: SLC6A2, SLC6A3, SLC6A4 💬 |
Alcoholism 8件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Serotonergic synapse, Synaptic vesicle cycle |
018 1件: 18 💬 |
105 |
Bupropion hydrochloride |
Bupropion |
3件: D00817 D00817, D07591 D07591, D07938 D07938 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
171 1件: 171 💬 |
106 |
Canakinumab (who approval pending) |
Canakinumab |
1件: D09315 D09315 💬 |
IL1B 1件: IL1B 💬 |
AGE-RAGE signaling pathway in diabetic complications 42件: AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
106 1件: 106 💬 |
107 |
Captopril |
Captopril |
1件: D00251 D00251 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
017 2件: 17, 86 💬 |
108 |
Cbd - oral solution, is known as epidiolex, and is the approved name in the usa. |
- |
- |
- |
- |
140 3件: 140, 144, 158 💬 |
109 |
Cbd - oral solution, is known as epidyolex, and is the approved name |
- |
- |
- |
- |
156 1件: 156 💬 |
110 |
Cbd oral solution, is known as epidyolex and is the approved name in the eu |
- |
- |
- |
- |
156 1件: 156 💬 |
111 |
Cbd-oral solution, is known as epidiolex, and is the approved name in the usa. |
- |
- |
- |
- |
158 1件: 158 💬 |
112 |
Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
113 |
Continuous apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
114 |
Corticosteroids (aprednislon) |
- |
- |
- |
- |
063 1件: 63 💬 |
115 |
Cr002 liquid api |
CR002 |
- |
- |
- |
299 1件: 299 💬 |
116 |
D-methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
117 |
D.3.2 product code where applicable13: |
- |
- |
- |
- |
193 1件: 193 💬 |
118 |
Delayed and extended release mesalazine |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
119 |
Device: apple watch and app |
Apple |
- |
- |
- |
070 1件: 70 💬 |
120 |
Device: endopath from itamar medical - fda approved device. |
- |
- |
- |
- |
096 1件: 96 💬 |
121 |
Device: novel allergen-specific immune signature directed approach to dietary elimination therapy |
- |
- |
- |
- |
098 1件: 98 💬 |
122 |
Device: therm-apptm th, thermographic camera |
- |
- |
- |
- |
070 1件: 70 💬 |
123 |
Dopaminergic agonist + apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
124 |
Duo-therapy with sildenafil + bosentan |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
125 |
Epidyolex and is the approved name in the eu |
- |
- |
- |
- |
156 1件: 156 💬 |
126 |
Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan) |
Bosentan |
6件: D01227 D01227, D02008 D02008, D02229 D02229, D07538 D07538, D08514 D08514, D10135 D10135 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
127 |
Eu-approved roactemra |
- |
- |
- |
- |
046 1件: 46 💬 |
128 |
Eur-1008 (apt-1008) |
- |
- |
- |
- |
299 1件: 299 💬 |
129 |
Eur-1008 (apt-1008) high dose |
- |
- |
- |
- |
298 1件: 298 💬 |
130 |
Eur-1008 (apt-1008) low dose |
- |
- |
- |
- |
298 1件: 298 💬 |
131 |
Firategrast (usan approved name) |
Firategrast |
1件: D06590 D06590 💬 |
ITGA4 1件: ITGA4 💬 |
Arrhythmogenic right ventricular cardiomyopathy 14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
013 1件: 13 💬 |
132 |
G04be03- sildenafil - sildenafil (citrato) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
133 |
Group 3: ustekinumab approximately 6 mg/kg |
Ustekinumab |
1件: D09214 D09214 💬 |
IL12A 3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
096 1件: 96 💬 |
134 |
Hydralazine |
Hydralazine |
2件: D01302 D01302, D08044 D08044 💬 |
AOC3 1件: AOC3 💬 |
Glycine, serine and threonine metabolism 5件: Glycine, serine and threonine metabolism, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, beta-Alanine metabolism |
067 1件: 67 💬 |
135 |
Hydrokortison apl kapsel 2,5 mg |
- |
- |
- |
- |
083 1件: 83 💬 |
136 |
Injection of apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
137 |
Interferon beta-1a (current approved manufacturing process invloving fbs) |
Human interferon beta |
1件: D04554 D04554 💬 |
IFNAR1 2件: IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 1件: 13 💬 |
138 |
Investigators choice of approved aed |
- |
- |
- |
- |
144 1件: 144 💬 |
139 |
Investigators choice of approved aeds |
- |
- |
- |
- |
144 1件: 144 💬 |
140 |
Irbesartan approved in the netherlands |
Irbesartan |
1件: D00523 D00523 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
066 1件: 66 💬 |
141 |
Irbesartan tablets (approved in the usa. reference listed drug avapro) ndc # 43547-0374-03 |
Irbesartan |
1件: D00523 D00523 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
066 2件: 66, 222 💬 |
142 |
Irbesartan tablets (ndc# 0955-1041-90 approved in the usa) |
Irbesartan |
1件: D00523 D00523 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
066 1件: 66 💬 |
143 |
Irbesartan tablets (ndc# 43547-0374-03 and ndc 43547-374-09, approved in the usa) generic tablets distributed by solco healthcare us, llc |
Irbesartan |
1件: D00523 D00523 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
222 1件: 222 💬 |
144 |
Irbesartan tablets (ndc# 43547-375-50 approved in the usa) generic tablets distributed by solco healthcare us, llc |
Irbesartan |
1件: D00523 D00523 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
066 1件: 66 💬 |
145 |
Iv apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
146 |
Kamada-api |
- |
- |
- |
- |
231 1件: 231 💬 |
147 |
Lithium apogepha |
- |
- |
- |
- |
002 1件: 2 💬 |
148 |
Locally approved intravenous contrast medium for contrast enhanced mri |
- |
- |
- |
- |
013 1件: 13 💬 |
149 |
Lorcaserin |
Lorcaserin |
1件: D06613 D06613 💬 |
- |
- |
140 1件: 140 💬 |
150 |
Mesalazine |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
046 3件: 46, 96, 97 💬 |
151 |
Mesalazine (3,600 mg) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
152 |
Mesalazine (asacol®) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
153 |
Mesalazine (mesalamine) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
096 1件: 96 💬 |
154 |
Mesalazine - tid 1000 mg |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
155 |
Mesalazine - tid 2x 500 mg |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
156 |
Mesalazine 1000 mg gastro-resistant tablets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
157 |
Mesalazine 250mg |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
158 |
Mesalazine 250mg tablet and nitazoxanide 500mg oral tablet |
Mesalazine |
2件: D00377 D00377, D02486 D02486 💬 |
- |
- |
097 1件: 97 💬 |
159 |
Mesalazine 4g enema |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
160 |
Mesalazine 500 mg gastro-resistant tablets (salofa |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
161 |
Mesalazine 500 mg gastro-resistant tablets (salofalk® 500 mg) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
162 |
Mesalazine ec 500 mg |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
096 1件: 96 💬 |
163 |
Mesalazine enema |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
164 |
Mesalazine liquid enema |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
165 |
Mesalazine slow-release granules |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
166 |
Mesalazine sustained-release tablets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
096 1件: 96 💬 |
167 |
Mesalazine tablet |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
168 |
Mesalazine tablets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
096 1件: 96 💬 |
169 |
Mesalazine with hydrocortisone sodium succinate |
Hydrocortisone |
2件: D00088 D00088, D00377 D00377 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
170 |
Mesalazine, tripterygium glycosides |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
096 1件: 96 💬 |
171 |
Methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 7件: 6 , 13, 34, 84, 113, 179, 206 💬 |
172 |
Methylphenidate (mpd) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 1件: 6 💬 |
173 |
Methylphenidate (overencapsulated) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
174 |
Methylphenidate 10mg tablets |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
175 |
Methylphenidate hydrochloride |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 2件: 6 , 13 💬 |
176 |
Methylphenidate modified release |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
177 |
Methylphenidate modified release 20 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
178 |
Methylphenidate modified release 30 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
179 |
Methylphenidate modified release 40 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
180 |
Methylphenidate, fluoxetin, risperidone |
Fluoxetine |
5件: D00326 D00326, D00426 D00426, D00823 D00823, D01296 D01296, D04999 D04999 💬 |
DRD2 5件: DRD2, HTR2A, SLC6A2, SLC6A3, SLC6A4 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Serotonergic synapse, Synaptic vesicle cycle, cAMP signaling pathway |
179 2件: 179, 206 💬 |
181 |
Mmx mesalamine/ mesalazine |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
182 |
Mmx mesalamine/mesalazine |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
183 |
Mmx mesalamine/mesalazine (high dose) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
184 |
Mmx mesalamine/mesalazine (low dose) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
185 |
Mono-therapy with sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
186 |
Non applicabile |
- |
- |
- |
- |
051 1件: 51 💬 |
187 |
Non applicable |
- |
- |
- |
- |
010 2件: 10, 19 💬 |
188 |
Oral sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
189 |
Other: controls primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
190 |
Other: mesalazine |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
191 |
Other: parkinson mpower mobile application |
- |
- |
- |
- |
006 1件: 6 💬 |
192 |
Other: real-time data capture app |
Bifenthrin |
- |
- |
- |
046 1件: 46 💬 |
193 |
Other: smartphone application |
- |
- |
- |
- |
049 1件: 49 💬 |
194 |
Other: standard of care sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
090 2件: 90, 301 💬 |
195 |
Overencapsulated mesalazine tablets |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
196 |
Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses |
- |
- |
- |
- |
046 1件: 46 💬 |
197 |
Pegcetacoplan (apl-2) |
- |
- |
- |
- |
002 2件: 2 , 62 💬 |
198 |
Piperazine |
Piperazine |
6件: D00807 D00807, D01393 D01393, D02127 D02127, D02145 D02145, D05486 D05486, D06224 D06224 💬 |
- |
- |
058 1件: 58 💬 |
199 |
Primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
200 |
Procedure: apheresis |
- |
- |
- |
- |
060 1件: 60 💬 |
201 |
Procedure: apheresis catheter placement |
- |
- |
- |
- |
096 1件: 96 💬 |
202 |
Recombinant human angiotensin-converting enzyme 2 (ace2), apn01 |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
203 |
Recombinant human apolipoprotein |
- |
- |
- |
- |
079 1件: 79 💬 |
204 |
Recombinant human apolipoprotein a-i |
- |
- |
- |
- |
079 1件: 79 💬 |
205 |
Recombinant human apolipoprotein a-i/phospholipids complex |
Omega-3 fatty acids |
- |
- |
- |
079 1件: 79 💬 |
206 |
Recombinant human apolipoprotein a1 |
- |
- |
- |
- |
079 1件: 79 💬 |
207 |
Riociguat granules 0.3% for oral application |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
208 |
S.c. apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
209 |
Sildenafil |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 17件: 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |
210 |
Sildenafil (50 mg) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
085 1件: 85 💬 |
211 |
Sildenafil (acute-1 hour) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
299 1件: 299 💬 |
212 |
Sildenafil (as citrate) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
213 |
Sildenafil (revatio) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
214 |
Sildenafil (revatio) 20 mg tid |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
215 |
Sildenafil (subchronic-4 weeks) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
299 1件: 299 💬 |
216 |
Sildenafil 20 mg tablets |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
278 1件: 278 💬 |
217 |
Sildenafil 20mg |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
051 2件: 51, 86 💬 |
218 |
Sildenafil 20mg and bosentan 62.5mg |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 2件: 51, 86 💬 |
219 |
Sildenafil 40mg oral capsule |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
299 1件: 299 💬 |
220 |
Sildenafil and losartan |
Losartan |
4件: D00357 D00357, D02229 D02229, D08146 D08146, D08514 D08514 💬 |
AGTR1 2件: AGTR1, PDE5A 💬 |
AGE-RAGE signaling pathway in diabetic complications 18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Purine metabolism, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
085 1件: 85 💬 |
221 |
Sildenafil by injection |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
210 1件: 210 💬 |
222 |
Sildenafil citrate |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
051 4件: 51, 85, 86, 225 💬 |
223 |
Sildenafil citrate (uk-92,480) |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
224 |
Sildenafil filmtabletten |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
225 |
Sildenafil singly or in association with bosentan |
Bosentan |
4件: D01227 D01227, D02229 D02229, D07538 D07538, D08514 D08514 💬 |
EDNRA 3件: EDNRA, EDNRB, PDE5A 💬 |
Calcium signaling pathway 11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
226 |
Sildenafil therapy |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
227 |
Sitaxsentan and sildenafil |
Sildenafil |
3件: D02229 D02229, D07171 D07171, D08514 D08514 💬 |
EDNRA 2件: EDNRA, PDE5A 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
228 |
Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth |
Dextrose, unspecified form |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
229 |
Spd476 (mesalazine) |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
230 |
Spd476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine |
Mesalazine |
1件: D00377 D00377 💬 |
- |
- |
097 1件: 97 💬 |
231 |
Spironolactone captopril carvedilol |
Captopril |
4件: D00251 D00251, D00255 D00255, D00443 D00443, D03415 D03415 💬 |
ACE 7件: ACE, ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, NR3C2 💬 |
AMPK signaling pathway 18件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
232 |
Subcutaneous apomorphine |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
233 |
Tadalafil and sildenafil |
Sildenafil |
3件: D02008 D02008, D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
113 1件: 113 💬 |
234 |
Tipranavir |
Tipranavir |
2件: D03843 D03843, D08605 D08605 💬 |
- |
- |
265 1件: 265 💬 |
235 |
Trifluoperazine |
Trifluoperazine |
3件: D00799 D00799, D01448 D01448, D08636 D08636 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
283 2件: 283, 284 💬 |
236 |
Trihexyphenidyl |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
005 2件: 5 , 6 💬 |
237 |
Ustekinumab (approximately 6 mg/kg) |
Ustekinumab |
1件: D09214 D09214 💬 |
IL12A 3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
049 1件: 49 💬 |
238 |
Ustekinumab approximately 6 mg/kg (iv) |
Ustekinumab |
1件: D09214 D09214 💬 |
IL12A 3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
096 1件: 96 💬 |
239 |
Volanesorsen sodium, apoc-iii antisense oligonucleotide |
Volanesorsen |
1件: D11648 D11648 💬 |
APOC3 1件: APOC3 💬 |
Cholesterol metabolism 2件: Cholesterol metabolism, PPAR signaling pathway |
265 1件: 265 💬 |
240 |
Wellbutrin (bupropion) |
Bupropion |
3件: D00817 D00817, D07591 D07591, D07938 D07938 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
096 1件: 96 💬 |